EOFlow Co., Ltd.
Founded in 2011 and listed on KOSDAQ in 2020, EOFlow manufactures the EOPatch wearable insulin pump for diabetes management.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEOFlow was founded on September 27, 2011 and listed on KOSDAQ on September 14, 2020 as a medical device manufacturer. Using electro-osmotic pump technology, it launched the wearable insulin pump EOPatch in 2021, controlled via the ADM controller or the Narsha smartphone app. EOPatch received Korean MFDS approval in 2017 with domestic sales starting April 2021, European CE marking in May 2021 with EU sales starting September 2022, UAE approval in August 2022 and Indonesia approval in October 2022, and its sensor-separated wearable artificial pancreas system received Korean MFDS approval in January 2024.
Products & technology
- EOPatchWearable, disposable insulin infusion device that continuously delivers insulin for blood glucose management in diabetes patients
- Sensor-separated wearable artificial pancreas systemAutomatically delivers insulin based on glucose readings via connection with a continuous glucose monitoring system (CGMS)
Regulatory approvals
data.go.kr5 Korean MFDS device approvals · 2015–2024
- MFDSInsulin infusion pump2024-01-30Product approval · Class 4제허 24-77 호
- MFDSInsulin infusion pump2021-11-10Product approval · Class 4제허 21-897 호
- MFDSInsulin infusion pump2021-03-23Product approval · Class 4제허 21-208 호
- MFDSInsulin infusion pump2017-12-19Product approval · Class 4제허 17-959 호
- MFDSInsulin infusion pumpRevoked2015-08-25Product approval · Class 4제허 15-1336 호
R&D and key agreements
Source: DART corporate disclosure센서일체형 웨어러블 인공췌장 시스템 · 당뇨 · 개발 중단 후 재개 예정 · Development was paused in 2023 under an M&A agreement with Medtronic (US); research is set to resume following the contract's termination
웨어러블 인공신장 · 개발 계획 · US subsidiary Nephria Bio was established and exclusive rights to Drexel University's MXene nanomaterial were secured for planned development; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025
웨어러블 비만치료제 및 NASH치료제 · 고도비만, NASH(비알콜성지방간염) · 합작법인 설립을 통한 개발 — 이후 중단 · Joint venture San Plena was established with UK-based Imperial College London venture Zihipp for development; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025
비인슐린 약물전달시스템(DDS) · 개발 및 공급 사업 확장 — 이후 중단 · Subsidiary Nova Pia (formerly Pharmeo) was established to develop and supply non-insulin DDS to pharmaceutical companies; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025
Companies in the same categoryMedical Devices
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Founded in 2000 and KOSDAQ-listed in 2013, i-SENS makes blood glucose monitors and point-of-care testing devices.
Founded in 2010 and KOSDAQ-listed in 2018, Sejong Medical manufactures laparoscopic surgical instruments.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Founded in 2015 and listed on KOSDAQ in 2022, Noul develops the on-device AI diagnostic platform miLab™ for blood and cancer testing.
KOSDAQ-listed manufacturer of diagnostic X-ray imaging systems and core components such as generators and tubes.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.
Founded in 1961 and KOSPI-listed in 1976, SBSUNGBO makes and sells crop protection agents (fungicides, insecticides, herbicides).
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition